Dr Markman previews the latest research on gynecologic cancer to be presented at the upcoming ASCO meeting.

Dr Kathy Miller points to PARP inhibitors and pertuzumab as highpoints of the breast cancer program at the upcoming ASCO meeting, including the plenary presentation of the OlympiAD trial.

Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.

Dr Jeffrey Weber previews five melanoma treatment studies that he considers the ones to watch; one, he predicts, will be practice-changing.

Experts on genomic testing in cancer discuss the marketing of NGS tests, and how they talk to their patients in light of the promise of ‘precision medicine.’

Experts respond to a Medscape survey of oncologists on the limits of genomic testing in cancer care.

From targeted therapy to radiotherapy, Dr Mark Kris previews what's ahead for lung cancer management from ASCO 2017.

Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer.

Dr Markman encourages review of recently reported possible effect of ovarian cancer antineoplastic agents in breast cancer patients with rare BRCA mutational signatures.

Reviewing the latest clinical management tools, Dr Arti Hurria talks about caring for the geriatric oncology patient long-term, without burning out.